Mostly preclinical research
A 2025 systematic review identified 35 preclinical studies, one small retrospective human report, and no clinical human safety data.
P—22 • Two-component research profile
BPC-157 / TB-500 Blend(BPC-157 10 mg + TB-500 10 mg)
A two-component research blend used for ingredient-level study of experimental tissue-response, cell-migration, actin-associated, and wound-model biology.
Name
BPC-157 / TB-500 Blend
Composition per vial: BPC-157 10 mg and TB-500 10 mg
- Scientific classification
- Blend of a synthetic 15-amino-acid BPC-157 peptide and the acetylated seven-amino-acid thymosin beta-4 fragment Ac-LKKTETQ
- Library family
- Regenerative
- Regulatory status
- Not FDA approved; in 2026 FDA proposed that the evaluated BPC-157 and TB-500 forms not be added to the 503A Bulks List
Compound overview
Two experimental peptides with separate research histories—and no established combination effect.
This blend places BPC-157 and TB-500 in one preparation, but the scientific evidence must still be read component by component. BPC-157 is a synthetic 15-amino-acid peptide studied mainly in animal models of tissue injury. TB-500 is an acetylated seven-amino-acid fragment associated with thymosin beta-4 research, actin biology, and cell movement.
A 2025 systematic review of BPC-157 and musculoskeletal research found 35 preclinical studies and only one small retrospective human report involving 12 people. The animal findings covered tendon, ligament, muscle, and bone models, while the review found no clinical human safety data. This makes the preclinical program interesting but leaves a substantial evidence gap.
For TB-500, a 2024 analytical study mapped the parent fragment and several metabolites in laboratory systems and rats. In its fibroblast wound assay, the parent TB-500 did not show the reported activity; one metabolite, Ac-LKKTE, did. That finding redirects attention toward metabolism and illustrates why results involving full thymosin beta-4 cannot automatically be assigned to TB-500.
No controlled study has established that combining BPC-157 with TB-500 creates an additive, complementary, or synergistic effect. The blend also introduces separate questions about compatibility, degradation, impurities, biological exposure, and whether either component changes the behavior of the other.
In July 2026, FDA reviewed BPC-157- and TB-500-related substances for possible inclusion on the 503A Bulks List and proposed that the evaluated free-base and acetate forms not be included. The reviews emphasized limited human evidence and unresolved characterization and safety questions; they did not establish an approved therapeutic use.
Metabolism may shape activity
A 2024 study found that one TB-500 metabolite—not the parent fragment—produced the measured wound-assay response in fibroblasts.
The blend itself is untested
Ingredient-level findings do not establish how the two peptides behave together or whether a combined effect exists.
Mechanism under study
Parallel tissue-response pathways without a proven blend mechanism
The components are associated with different experimental pathways. Packaging them together does not demonstrate biological cooperation.
Cell and vascular responses
BPC-157 studies examine cell migration, inflammatory signals, blood-vessel responses, and structural outcomes in animal injury models.
Actin and fragment metabolism
TB-500 research follows an actin-associated thymosin beta-4 fragment and the metabolites that may influence cell movement in laboratory assays.
Combination uncertainty
No controlled evidence defines the blend's stability, exposure, interaction, safety, or biological effect compared with either component alone.
Research involving BPC-157, full-length thymosin beta-4, TB-500, or a TB-500 metabolite is not interchangeable, and none of it proves a benefit from the combined preparation.
Current research areas
Questions under investigation
- How BPC-157 affects cells and tissues in injury models
- How TB-500 breaks down and which fragments remain biologically active
- How cells move and reorganize their internal structure
- Whether the two ingredients remain stable and compatible when combined
- Whether laboratory findings translate safely and meaningfully to people
Evidence summary
Two active research questions, not one proven combination
- BPC-157 research map: Animal studies provide several models for examining tendon, ligament, muscle, bone, vascular, and inflammatory responses.
- TB-500 metabolism: Modern analytical work can distinguish the parent fragment from its breakdown products and test which form produces a measurable laboratory response.
- Cell-movement models: The component research offers ways to study actin-associated movement and tissue-response pathways under controlled conditions.
- Combination science: The untested blend creates a clear need for compatibility, stability, pharmacology, and interaction studies before combined effects can be characterized.
- Evidence improvement: Better material characterization and carefully controlled human research would help separate reproducible findings from marketing claims.
The ingredients have separate preclinical research rationales, but the complete blend has no established clinical benefit, dosing standard, human safety profile, or demonstrated synergy.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, injury or recovery guidance, dosing information, or instructions for BPC-157, TB-500, or the blend. Neither ingredient nor the combination is FDA approved. FDA's 2026 reviews proposed excluding the evaluated BPC-157 and TB-500 forms from the 503A Bulks List and identified unresolved evidence, characterization, impurity, and safety questions. The blend is labeled Research Use Only — Not for Human Consumption, and research-market materials should not be assumed to match substances used in published studies.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.